Skip to main content
. 2014 Dec 18;2014:352925. doi: 10.1155/2014/352925

Table 2.

Expression of EGFR, p-ERK1/2, p-STAT3, ERCC1, and Akt by immunohistochemistry, and clinicopathological characteristics in 96 patients with lung adenocarcinoma.

Group EGFR mean score P value pERK1/2 positivity (%) P value p-STAT3 positivity (%) P value p-Akt positivity (%) P value ERCC1 positivity (%) P value
Sex
 Male 122.4 0.19 7 (7.61) 0.5 14 (15.3) 0.2 4 (4.3) 0.4 18 (20.4) 0.6
 Female 91.0 7 (7.61) 15 (16.4) 8 (8.6) 21 (23.8)
Age
  Below 60 years 82.2 0.14 3 (3.2) 0.17 8 (8.7) 0.2 5 (5.3) 0.8 12 (13.6) 0.17
  Above 60 years 177.8 11 (11.9) 21 (23) 7 (7.5) 27 (30.6)
Size/stage
 T1 70.0 0.01 8 (8.7) 0.22 11 (12) 0.7 6 (6.4) 0.5 18 (20.4) 0.4
 Greater than T1 129.1 6 (6.5) 18 (19.7) 6 (6.4) 21 (23.8)
Vascular invasion
 Yes 80.1 0.01 2 (2.2) 0.05 11 (12.3) 0.9 2 (2.2) 0.05 12 (13.9) 0.2
 No 141.7 12 (13.3) 18 (20.2) 11 (12) 26 (30.2)
Pleural invasion
 Yes 90.4 0.07 2 (2.2) 0.3 8 (8.9) 0.5 1 (1.1) 0.1 10 (11.6) 0.7
 No 142.1 13 (13.9) 21 (23.6) 11 (12) 28 (32.5)
High grade histology
 Yes 155.5 <0.01 3 (3.2) 0.5 9 (9.8) 0.6 5 (5.3) 0.3 13 (14.7) 0.5
 No* 84.4 11 (11.9) 20 (21.9) 7 (7.5) 26 (29.5)

*Predominantly solid or acinar cribriform tumors (high grade) versus other subtypes.